Argus’ Jacob Kilstein reiterated a Buy rating on Metlife Inc (NYSE: MET), while lowering the price target from $62 to $54. “Our rating reflects the stock’s attractive valuation, as well as the company’s global initiatives and efforts to return cash to shareholders,... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to: